glp-1 medication weight loss timeline Specialist in Langhorne and Philadelphia, PA GLP-1 Weight Loss in Connecticut

Bariatricmetabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial

The CagriSema combination represents a paradigm shift in obesity pharmacotherapy, producing mean weight loss (22.7%) that approaches bariatric surgery efficacy without invasive procedures

Janssens nipocalimab tackles hemolytic disease of the fetus and newborn

doi: 10.1016/S0891-5849(97)00371-7

Keep you feeling full longer - smaller portions are enough

Previously only available as an injectable, semaglutides oral formulation could expand treatment for patients who are reluctant to use an Read More In a post-hoc analysis of a trial that measured weight gain and cardiometabolic factors among participants who used tirzepatide for 36 weeks, researchers found that among participants with obesity who stopped tirzepatide, a large majority had regained much of their weightand that majority also lost more of the cardiometabolic benefits compared to those who maintained their weight reduction